Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose reduction versus switch to ziprasidone, followed by clozapine if ineffective, in long-stay schizophrenia
NL-OMON24705Recruiting
- Sponsor
- Rivierduinen
- Start
- Jul 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ziprasidone, clozapine and haloperidol in schizophrenia and schizoaffective disorder (2 arms), sponsored by Rivierduinen. Primary endpoints: PANSS negative symptoms scale and CGI therapeutic effect scale. Started Jul 2007; status: recruiting.
02
Drugs
ziprasidoneclozapinehaloperidol
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NL-OMON24705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24705.